naltrexone and Colitis, Mucous

naltrexone has been researched along with Colitis, Mucous in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Do Rego, JC; Fichna, J; Grzywacz, D; Kamysz, W; Polepally, PR; Sałaga, M; Sibaev, A; Sobczak, M; Storr, M; Zjawiony, JK	1
Cami-Kobeci, G; Fichna, J; Husbands, S; Jarmuż, A; Wasilewski, A; Zielińska, M	1
Dekel, R; Grenshpon, R; Halpern, Z; Kariv, R; Ringel, Y; Tiomny, E; Waisman, G	1
Baxter, K; Burton, D; Camilleri, M; Foxx-Orenstein, AE; McKinzie, S; Szarka, LA; Thomforde, G; Zinsmeister, AR	1

Trials

2 trial(s) available for naltrexone and Colitis, Mucous

Article	Year
Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study. Digestive diseases and sciences, 2006, Volume: 51, Issue:12 Topics: Abdominal Pain; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Treatment Outcome	2006
Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. Neurogastroenterology and motility, 2007, Volume: 19, Issue:10 Topics: Adult; Constipation; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Motility; Humans; Indoles; Irritable Bowel Syndrome; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Radionuclide Imaging; Serotonin 5-HT4 Receptor Agonists; Serotonin Receptor Agonists	2007

Article

Year

Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study.

Digestive diseases and sciences, 2006, Volume: 51, Issue:12

Topics: Abdominal Pain; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Treatment Outcome

2006

Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.

Neurogastroenterology and motility, 2007, Volume: 19, Issue:10

Topics: Adult; Constipation; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Motility; Humans; Indoles; Irritable Bowel Syndrome; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Radionuclide Imaging; Serotonin 5-HT4 Receptor Agonists; Serotonin Receptor Agonists

2007

Other Studies

2 other study(ies) available for naltrexone and Colitis, Mucous

Article	Year
Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. The Journal of pharmacology and experimental therapeutics, 2014, Volume: 350, Issue:1 Topics: Abdominal Pain; Administration, Oral; Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Diarrhea; Disease Models, Animal; Diterpenes, Clerodane; Dose-Response Relationship, Drug; Exploratory Behavior; Gastrointestinal Motility; Injections, Intraperitoneal; Irritable Bowel Syndrome; Male; Mice; Motor Activity; Naltrexone; Receptors, Opioid, kappa; Receptors, Opioid, mu	2014
Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome. Pharmacological reports : PR, 2017, Volume: 69, Issue:2 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Abdominal Pain; Analgesics; Analgesics, Opioid; Animals; Colon; Diarrhea; Disease Models, Animal; Gastrointestinal Motility; Gastrointestinal Transit; Irritable Bowel Syndrome; Male; Mice; Mice, Inbred BALB C; Muscle Contraction; Muscle, Smooth; Naloxone; Naltrexone; Receptors, Opioid; Thebaine	2017

Article

Year

Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

The Journal of pharmacology and experimental therapeutics, 2014, Volume: 350, Issue:1

Topics: Abdominal Pain; Administration, Oral; Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Diarrhea; Disease Models, Animal; Diterpenes, Clerodane; Dose-Response Relationship, Drug; Exploratory Behavior; Gastrointestinal Motility; Injections, Intraperitoneal; Irritable Bowel Syndrome; Male; Mice; Motor Activity; Naltrexone; Receptors, Opioid, kappa; Receptors, Opioid, mu

2014

Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome.

Pharmacological reports : PR, 2017, Volume: 69, Issue:2

Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Abdominal Pain; Analgesics; Analgesics, Opioid; Animals; Colon; Diarrhea; Disease Models, Animal; Gastrointestinal Motility; Gastrointestinal Transit; Irritable Bowel Syndrome; Male; Mice; Mice, Inbred BALB C; Muscle Contraction; Muscle, Smooth; Naloxone; Naltrexone; Receptors, Opioid; Thebaine

2017